CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Relationship between therapeutic effects on infarct size in acute myocardial infarction and therapeutic effects on 1-year outcomes: A patient-level analysis of randomized clinical trials 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor Cardiorespiratory Fitness and Mortality in Healthy Men and Women The Year in Cardiovascular Medicine 2020: Coronary Intervention Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients Is Cardiac Diastolic Dysfunction a Part of Post-Menopausal Syndrome? Prevalence of Angina Among Primary Care Patients With Coronary Artery Disease

Original Research2017 Jun;188:18-25.

JOURNAL:Am Heart J. Article Link

Relationship between therapeutic effects on infarct size in acute myocardial infarction and therapeutic effects on 1-year outcomes: A patient-level analysis of randomized clinical trials

Selker HP, Udelson JE, Ruthazer R et al. Keywords: infarct size; therapeutic effects; acute myocardial infarction

ABSTRACT


BACKGROUND - While infarct size in patients with ST-segment elevation myocardial infarction (STEMI) has been generally associated with long-term prognosis, whether a therapeutic effect on infarct size has a corresponding therapeutic effect on long-term outcomes is unknown.


METHODS - Using combined patient-level data from 10 randomized trials of primary percutaneous coronary intervention (PCI) for STEMI, we created multivariable Cox proportional hazard models for one-year heart failure hospitalization and all-cause mortality, which included clinical features and a variable representing treatment effect on infarct size. The trials included 2679 participants; infarct size was measured at a median 4 days post infarction.


RESULTSMean infarct size among the control groups ranged from 16% to 35% of the left ventricle, and from 12% to 36% among treatment groups. There was a significant relationship between treatment effect on infarct size and treatment effect on 1-year heart failure hospitalization (HR 0.85, 95% CI 0.77-0.93, P=.0006), but not on one-year mortality (HR 0.97, 95% CI 0.89-1.06). The treatment effect between infarct size and heart failure hospitalization was stable in sensitivity analyses adjusting for time from STEMI onset to infarct size assessment, and when considering heart failure as the main outcome and death as a competing risk.


CONCLUSIONS - We conclude that early treatment-induced effects on infarct size are related in direction and magnitude to treatment effects on heart failure hospitalizations. This finding enables consideration of using infarct size as a valid surrogate outcome measure in assessing new STEMI treatments.


Copyright © 2017 Elsevier Inc. All rights reserved.